Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

siRNA Screen Identifies Potential Cystic Fibrosis Drug Target

By BiotechDaily International staff writers
Posted on 26 Sep 2013
Image: Inhibiting DGKi reduces ENaC activity, reversing the effects of cystic fibrosis. In this assay, the green glow dims more in cells with active ENaC (bottom), so the scientists screened for cases where the cells’ glow barely changed (top) (Photo courtesy of Dr. Rainer Pepperkok, European Molecular Biology Laboratory).
Image: Inhibiting DGKi reduces ENaC activity, reversing the effects of cystic fibrosis. In this assay, the green glow dims more in cells with active ENaC (bottom), so the scientists screened for cases where the cells’ glow barely changed (top) (Photo courtesy of Dr. Rainer Pepperkok, European Molecular Biology Laboratory).
A large-scale screen combining high-content live-cell microscopy and small interfering RNAs (siRNAs) in human airway epithelial cells from patients with cystic fibrosis (CF) has pinpointed a promising target for drug treatment.

Cystic fibrosis is an inherited disease caused by a mutation in the CFTR (cystic fibrosis transmembrane conductance regulator) gene that affects the body's ability to move salt and water in and out of cells. CTFR codes for an ABC transporter-class ion channel, ENaC, which transports chloride and thiocyanate ions across epithelial cell membranes. Mutations of the CFTR gene disrupt the functioning of ENaC chloride ion channels in these cell membranes, leading to cystic fibrosis.

All disease-causing mutations in the CFTR gene prevent the channel from functioning properly, leading to a blockage of the movement of salt and water into and out of cells. As a result of this blockage, cells that line the passageways of the lungs, pancreas, and other organs produce abnormally thick, sticky mucus. This mucus obstructs the airways and glands, causing the characteristic signs and symptoms of cystic fibrosis. While thin mucus can be removed by cilia, thick mucus cannot be removed by cilia, so it traps bacteria that give rise to chronic infections. The only drug currently available that directly counteracts a cystic fibrosis-related mutation only works on the 3% of patients that carry one specific mutation out of the almost 2000 CFTR mutations detected so far.

Investigators at the European Molecular Biology Laboratory (Heidelberg, Germany) and their colleagues at the University of Lisbon (Portugal) sought to develop a global understanding of molecular regulators of ENaC traffic and function and to identify candidate CF drug targets. To this end, they performed a large-scale screen combining high-content live-cell microscopy and siRNAs in human airway epithelial cells.

A study published in the September 12, 2013, online edition of the journal Cell revealed that the investigators screened over 6,000 genes and identified over 1,500 candidates, evenly divided between channel inhibitors and activators.

Genes in the phosphatidylinositol pathway were enriched on the primary candidate list, and these, along with other ENaC activators, were examined further with secondary siRNA validation. Subsequent detailed investigation revealed ciliary neurotrophic factor receptor (CNTFR) as an ENaC modulator and showed that inhibition of DGKi (diacylglycerol kinase, iota), a protein involved in phosphatidylinositol biphosphate (PiP2) metabolism, downgraded ENaC activity, leading to normalization of both Na+ and fluid absorption in CF airways to non-CF levels in primary human lung cells from CF patients.

“Inhibiting DGKi seems to reverse the effects of cystic fibrosis, but not block ENaC completely,” said senior author Dr. Margarida Amaral, professor of chemistry and biochemistry at the University of Lisbon, “indeed, inhibiting DGKi reduces ENaC activity enough for cells to go back to normal, but not so much that they cause other problems, like pulmonary edema.”

Related Links:

European Molecular Biology Laboratory
University of Lisbon



Channels

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.